Total Payments
$3,311
2023 Payments
$168.95
Companies
23
Transactions
191
Medicare Patients
2,356
Medicare Billing
$241,478
Payment Breakdown by Category
Food & Beverage$3,311 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,311 | 191 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $821.49 | 47 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $570.87 | 36 | $0 (2023) |
| Gilead Sciences, Inc. | $283.88 | 13 | $0 (2023) |
| Janssen Biotech, Inc. | $266.69 | 13 | $0 (2022) |
| Boston Scientific Corporation | $194.88 | 10 | $0 (2022) |
| Allergan Inc. | $192.14 | 14 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $181.91 | 14 | $0 (2022) |
| Celgene Corporation | $180.64 | 10 | $0 (2023) |
| Valeant Pharmaceuticals North America LLC | $153.46 | 8 | $0 (2017) |
| INTERCEPT PHARMACEUTICALS, INC. | $75.90 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $168.95 | 8 | Celgene Corporation ($55.98) |
| 2022 | $737.60 | 36 | Janssen Biotech, Inc. ($183.15) |
| 2021 | $205.32 | 11 | Celgene Corporation ($70.90) |
| 2020 | $98.33 | 6 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($47.16) |
| 2019 | $839.45 | 48 | AbbVie, Inc. ($271.99) |
| 2018 | $770.81 | 51 | AbbVie, Inc. ($168.15) |
| 2017 | $490.10 | 31 | Valeant Pharmaceuticals North America LLC ($153.46) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/12/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Gastroenterology | ||||||
| 03/23/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $14.88 | General |
| 03/03/2023 | NESTLE HEALTHCARE NUTRITION INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $21.98 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 02/22/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $19.32 | General |
| 02/09/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.78 | General |
| Category: Neuroscience | ||||||
| 02/02/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.09 | General |
| 01/19/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.51 | General |
| 01/12/2023 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/19/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $33.82 | General |
| Category: Immunology | ||||||
| 12/19/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $33.82 | General |
| Category: Immunology | ||||||
| 12/12/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: Gastroenterology | ||||||
| 12/07/2022 | Boston Scientific Corporation | CRE PRO (Device) | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: CRE_ENDO | ||||||
| 11/21/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: Immunology | ||||||
| 11/21/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: Immunology | ||||||
| 10/13/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Immunology | ||||||
| 10/04/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.97 | General |
| 09/27/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: Gastroenterology | ||||||
| 09/01/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.02 | General |
| Category: Neuroscience | ||||||
| 08/29/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: Immunology | ||||||
| 08/25/2022 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/04/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: IMMUNOLOGY | ||||||
| 07/18/2022 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/30/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.82 | General |
| Category: Neuroscience | ||||||
| 06/27/2022 | Boston Scientific Corporation | CRE PRO (Device) | Food and Beverage | In-kind items and services | $38.73 | General |
| Category: CRE_ENDO | ||||||
| 06/20/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: INTERNAL MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 154 | 216 | $52,370 | $15,371 |
| 2022 | 16 | 720 | 998 | $235,043 | $79,128 |
| 2021 | 16 | 692 | 970 | $241,468 | $69,159 |
| 2020 | 17 | 790 | 1,150 | $284,155 | $77,819 |
Total Patients
2,356
Total Services
3,334
Medicare Billing
$241,478
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $8,910 | $2,665 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 29 | $5,075 | $2,508 | 49.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 13 | 13 | $7,597 | $2,446 | 32.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 24 | $6,960 | $2,217 | 31.8% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 22 | 55 | $6,875 | $2,053 | 29.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 19 | 19 | $9,882 | $1,700 | 17.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 14 | $2,682 | $876.40 | 32.7% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2023 | 13 | 21 | $2,541 | $556.02 | 21.9% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 12 | 21 | $1,848 | $351.43 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 145 | 178 | $31,150 | $16,526 | 53.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 51 | 52 | $30,612 | $10,151 | 33.2% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 67 | 215 | $26,875 | $9,516 | 35.4% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 70 | 73 | $31,609 | $7,848 | 24.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 77 | 132 | $23,628 | $7,487 | 31.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 58 | 60 | $29,762 | $5,734 | 19.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 32 | $7,360 | $4,424 | 60.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $5,676 | $3,777 | 66.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $11,454 | $3,502 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 47 | $5,452 | $2,748 | 50.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 24 | $6,168 | $1,938 | 31.4% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2022 | 24 | 33 | $2,904 | $1,457 | 50.2% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 16 | 16 | $4,852 | $1,334 | 27.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 18 | 18 | $10,061 | $1,114 | 11.1% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Office | 2022 | 27 | 40 | $4,840 | $1,076 | 22.2% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 22 | 22 | $2,640 | $496.36 | 18.8% |
About Dr. Stephen Gerrish, MD
Dr. Stephen Gerrish, MD is a Hepatology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1639369226.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Gerrish, MD has received a total of $3,311 in payments from pharmaceutical and medical device companies, with $168.95 received in 2023. These payments were reported across 191 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($3,311).
As a Medicare-enrolled provider, Gerrish has provided services to 2,356 Medicare beneficiaries, totaling 3,334 services with total Medicare billing of $241,478. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Hepatology
- Other Specialties Gastroenterology
- Location Tampa, FL
- Active Since 07/30/2007
- Last Updated 02/17/2012
- Taxonomy Code 207RI0008X
- Entity Type Individual
- NPI Number 1639369226
Products in Payments
- XIFAXAN (Drug) $496.41
- Humira (Biological) $403.39
- REMICADE (Biological) $173.17
- LINZESS (Drug) $170.28
- ZEPOSIA (Drug) $146.44
- APRISO (Drug) $120.87
- STELARA (Biological) $93.52
- Creon (Drug) $86.00
- CREON (Drug) $78.67
- Entyvio (Biological) $78.05
- OCALIVA (Drug) $75.90
- Amitiza (Drug) $73.69
- VIBERZI (Drug) $72.82
- CRE PRO (Device) $66.08
- Trulance (Drug) $63.65
- HUMIRA (Biological) $62.00
- RINVOQ (Biological) $55.99
- ZENPEP (Drug) $55.78
- TRULANCE (Drug) $52.76
- CAPTIVATOR COLD (Device) $52.54
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.